Skip to content
Back to Investors
EC

Exceptional Capital

Venture Capital

Exceptional Ventures is an early-stage Venture Capital firm based in London that invests in high-impact businesses focused on helping people live happier, healthier, and longer lives, while championing a sustainable planet.

Portfolio

13

companies

Investment by month

By category

  • AI/ML£25.5M
  • MedTech£18.1M
  • HealthTech£17.0M
  • Marketplace£6.0M
  • InsurTech£3.6M
  • Other£2.8M

By location

  • London£68.8M
  • Hertfordshire£2.3M
  • United Kingdom£1.8M

Portfolio companies

Big Picture Bio

Big Picture Bio

AI-driven drug discovery platform designing optimal cancer combination therapies.

CH

Clerkenwell Health

Clerkenwell Health operates a specialist clinical research facility for psychedelic assisted therapies.

E

Evaro

Evaro operates a healthcare-as-a-service platform for consumer applications.

Gladys

Gladys

Gladys provides an artificial intelligence platform to connect families with local care workers.

GL

Gradient Labs

Gradient Labs builds artificial intelligence agents for automated financial operations.

I

InTouchNow

AI voice agent platform for general practices.

View all 13 companies

Team

MC

Matt Cooper

Chairman

MB

Michella Botto

Investment Manager

Paolo Pio

Paolo Pio

Co-Founder and General Partner

Paolo operates as a co-founder and general partner at Exceptional Ventures. He also invests across several companies and trains at Urban Tribe Life.

LinkedIn

Recent investments

Seed
£2.3M

Ada Ventures leads the seed round to support the development of AI voice agents for general practices.

"For most patients, the GP reception desk is the front door to the entire NHS, and it’s under more strain than any other part of the system. InTouchNow was built to handle the repetitive, time-consuming calls so reception teams can focus on the patients who really need a person. Ada’s backing is a strong vote of confidence in British healthtech, and lets InTouchNow bring safe, ethical, and genuinely useful AI to many more NHS practices across the UK."
— Daniel Park, Founder
Pre-Seed
£1.5M

The pre-seed round was co-led by Kadmos Capital and Exceptional Ventures and will support the transition of designed drug combinations into wet-lab validation.

"Cancer is not one disease driven by one target, but we still develop drugs as if it were. Combinations are how we beat it – and with more than 900 billion of them possible, no lab on earth can test its way to the right ones. That is the problem we built Big Picture Bio to solve: model the disease as the dynamic system it actually is, then design against it – combinations chosen because they are most likely to work in patients, not because they were the ones we could get to. This funding takes our first designed combinations out of the model and into the lab."
— Kerstin Papenfuss, CEO and co-founder
Series A
$13.0M

Octopus Ventures and CommerzVentures joined the round to support international expansion and product development.

"What we’re building is the agent layer that financial services need to run their customer operations autonomously. It has to work the way they do, connect to the systems they have already built, and handle the long-running work that has stayed manual until now"
— Dimitri Masin, Co-founder and CEO
Seed
£2.0M

The seed round was co-led by Shilling and Plus Partners to accelerate commercial expansion across the UK and Spain.

"Dementia is never just one person’s disease. It affects entire families, and carers often carry an enormous invisible burden."
— Anna Muñoz-Farré, CEO and co-founder